{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:23:10Z","timestamp":1791469390685,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/s00277-011-1276-2","type":"journal-article","created":{"date-parts":[[2011,6,22]],"date-time":"2011-06-22T08:57:36Z","timestamp":1308733056000},"page":"1161-1166","source":"Crossref","is-referenced-by-count":52,"title":["Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma"],"prefix":"10.1007","volume":"90","author":[{"given":"Marek","family":"Hus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Grzasko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Szostek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Pluta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Woszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Adamczyk-Cioch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Jawniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Legiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Morawska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Kozinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Waci\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dmoszynska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,23]]},"reference":[{"key":"1276_CR1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/CCO.0b013e3283136984","volume":"20","author":"J Blade","year":"2008","unstructured":"Blade J, Rosinol L (2008) Advances in therapy of multiple myeloma. Curr Opin Oncol 20:697\u2013704","journal-title":"Curr Opin Oncol"},{"key":"1276_CR2","first-page":"404","volume":"86","author":"M Hus","year":"2001","unstructured":"Hus M, Dmoszynska A, Soroka-Wojtaszko M et al (2001) Thalidomide treatment of resistant or relapsed multiple myeloma. Haematologica 86:404\u2013408","journal-title":"Haematologica"},{"key":"1276_CR3","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565\u20131571","journal-title":"N Engl J Med"},{"key":"1276_CR4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2003-04-1045","volume":"103","author":"B Barlogi","year":"2004","unstructured":"Barlogi B, Shaughnessy J, Tricot G et al (2004) Treatment of multiple myeloma. Blood 103:20\u201332","journal-title":"Blood"},{"key":"1276_CR5","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1182\/blood-2006-08-042275","volume":"109","author":"A Palumbo","year":"2007","unstructured":"Palumbo A, Ambrosini MT, Benevolo G et al (2007) Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109:2767\u20132772","journal-title":"Blood"},{"key":"1276_CR6","doi-asserted-by":"crossref","first-page":"145e","DOI":"10.1016\/j.leukres.2009.03.015","volume":"23","author":"A Corso","year":"2009","unstructured":"Corso A, Zappasodi P, Barbarano L et al (2009) Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. Leukemia Res 23:145e\u2013149e","journal-title":"Leukemia Res"},{"key":"1276_CR7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/carcin\/23.3.521","volume":"23","author":"B Agarwal","year":"2002","unstructured":"Agarwal B, Halmos B, Feoktistov AS et al (2002) Mechanism of lovastatin-induced apoptosis in intestinal intestinal epithelial cells. Carcinogenesis 23:521\u2013528","journal-title":"Carcinogenesis"},{"key":"1276_CR8","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/1535-7163.MCT-06-0745","volume":"6","author":"WW Wong","year":"2007","unstructured":"Wong WW, Clendening JW, Martirosyan A et al (2007) Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma. Mol Cancer Ther 6:1886\u20131897","journal-title":"Mol Cancer Ther"},{"key":"1276_CR9","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood-2003-03-0970","volume":"102","author":"NW Donk Van de","year":"2003","unstructured":"Van de Donk NW, Kamphuis MM, Van Kessel B et al (2003) Inhibition of protein geranylgeranylation induced apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 102:3354\u20133362","journal-title":"Blood"},{"key":"1276_CR10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.leukres.2006.07.018","volume":"31","author":"C Baulch-Brown","year":"2007","unstructured":"Baulch-Brown C, Molloy TJ, Yeh SL et al (2007) Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. Leuk Res 31:341\u2013352","journal-title":"Leuk Res"},{"key":"1276_CR11","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/sj.leu.2402501","volume":"16","author":"NW Donk Van de","year":"2002","unstructured":"Van de Donk NW, Kamphuls MM, Lokhorst HM et al (2002) The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 16:1362\u20131371","journal-title":"Leukemia"},{"key":"1276_CR12","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/(SICI)1097-0215(19990517)81:4<560::AID-IJC10>3.0.CO;2-7","volume":"81","author":"W Feleszko","year":"1999","unstructured":"Feleszko W, Balkowiec E, Sieberth E et al (1999) Lovastatin and TNF alpha exhibit potentiated antitumor effects against Ha-ras transformer marine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer 81:560\u2013567","journal-title":"Int J Cancer"},{"key":"1276_CR13","first-page":"483","volume":"2","author":"A Thibault","year":"1996","unstructured":"Thibault A, Samid D, Tompkims AC (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2:483\u2013491","journal-title":"Clin Cancer Res"},{"key":"1276_CR14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1211\/0022357023187","volume":"56","author":"A Dmoszynska","year":"2004","unstructured":"Dmoszynska A, Podhorecka M, Rolinski J et al (2004) Influence of lovastatin on BCL-2 and BAX expression by plasma cells and T lymphocytes in short-term cultures of multiple myeloma bone marrow mononuclear cells. Pol J Pharmacology 56:485\u2013489","journal-title":"Pol J Pharmacology"},{"key":"1276_CR15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hon.869","volume":"27","author":"TE Sondergaard","year":"2009","unstructured":"Sondergaard TE, Pedersen PT, Andersen TL et al (2009) A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Hematol Oncol 27:17\u201322","journal-title":"Hematol Oncol"},{"key":"1276_CR16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0609.2008.01121.x","volume":"81","author":"M Lilienfeld-Toal","year":"2008","unstructured":"Lilienfeld-Toal M, Hahn-Ast C, Furkert K et al (2008) A systematic review of phase II trials of thalidomide\/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol 81:247\u2013252","journal-title":"Eur J Haematol"},{"key":"1276_CR17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1600-0609.2007.00908.x","volume":"79","author":"H Murakami","year":"2007","unstructured":"Murakami H, Handa H, Abe M et al (2007) Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. Eur J Haematol 79:234\u2013239","journal-title":"Eur J Haematol"},{"key":"1276_CR18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/sj.thj.6200403","volume":"5","author":"A Palumbo","year":"2004","unstructured":"Palumbo A, Bertola A, Falco P et al (2004) Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 5:318\u2013334","journal-title":"Hematol J"},{"key":"1276_CR19","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04345.x","volume":"121","author":"A Anagnostopoulos","year":"2003","unstructured":"Anagnostopoulos A, Weber D, Rankin K et al (2003) Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:768\u2013771","journal-title":"Br J Haematol"},{"key":"1276_CR20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2783.x","volume":"77","author":"MT Cibeira","year":"2006","unstructured":"Cibeira MT, Rosinol L, Ramiro L et al (2006) Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. Eur J Haematol 77:486\u2013492","journal-title":"Eur J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00277-011-1276-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T13:58:50Z","timestamp":1592661530000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-011-1276-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,23]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["1276"],"URL":"https:\/\/doi.org\/10.1007\/s00277-011-1276-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,23]]}}}